Focus: Viatris (China) is a Shanghai-based generics and small-molecule company focused on COPD, cardiovascular, and CNS therapeutics with a diversified portfolio of post-LOE assets.
Profile data last refreshed 3h ago · AI intelligence enriched 2w ago
Stable — net -3 jobs in 30d
166 added, 169 removed. Backfill posture.
Viable for commercial, regulatory, and operations professionals seeking stable generics-focused roles, but R&D and pipeline-betting careers should look elsewhere given zero trial activity.
Anchor franchise (32% of revenue); generic inhaled corticosteroid/LABA combination facing competitive pressure but stable Part D utilization.
Help build intelligence for Viatris
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Viatris's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Second-largest revenue driver at risk; patent cliff in 4.7 years will eliminate exclusivity unless brand loyalty or formulation advantages sustain sales.
Stable generic atypical antipsychotic with established market position; part of diversified portfolio across psychiatry.
Co-equal CNS franchise facing eventual LOE; controlled-substance status and high reimbursement support current revenue plateau.
Inhalation corticosteroid with established label; approaching LOE but smaller revenue base limits portfolio impact.
Mature statin franchise well past primary patent cliff; declining revenue reflects generic saturation and GLP-1 competitive pressure.
Generic oncology tyrosine-kinase inhibitor with niche indications; stable revenue reflects specialty cancer market utilization.
Mature bisphosphonate franchise facing demographic headwinds and shifting osteoporosis treatment paradigm toward newer agents.
Extended-release SNRI with established psychiatric franchise; approaching LOE but sustained by brand loyalty and formulary positioning.
Opioid portfolio entry (pre-launch status unclear); potential growth offset by regulatory scrutiny and pain-management practice shifts toward multimodal approaches.
300 discontinued, 291 duplicate formulations not shown
+42 more products with revenue data
Zacks Industry Outlook Highlights Amphastar Pharmaceuticals, Sandoz and Viatris - Yahoo Finance
Zacks Industry Outlook Highlights Amphastar Pharmaceuticals, Sandoz and Viatris Yahoo Finance
Cavendish reiterates 'buy' rating on Shield Therapeutics after US deal with Viatris - Proactive Investors
Cavendish reiterates 'buy' rating on Shield Therapeutics after US deal with Viatris Proactive Investors
Challenge and opportunity in Ireland’s regulatory pharma space - Silicon Republic
Challenge and opportunity in Ireland’s regulatory pharma space Silicon Republic
Viatris (VTRS) Stock Trades At A Discount To Sales Despite A 76% Run - simplywall.st
Viatris (VTRS) Stock Trades At A Discount To Sales Despite A 76% Run simplywall.st
Viatris posts Q2 beat; sells eye drug Tyrvaya to Harrow for up to $100M - Seeking Alpha
Viatris posts Q2 beat; sells eye drug Tyrvaya to Harrow for up to $100M Seeking Alpha
Viatris (VTRS) Holds Firm at $17.7 as Shares Push Higher by 0.40% - Force Index - vinanet.vn
Viatris (VTRS) Holds Firm at $17.7 as Shares Push Higher by 0.40% - Force Index vinanet.vn
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Source: state DOL filings, aggregated via Big Local News
+219 more products
Structural cost pressures evident; roles in consolidating manufacturing and operations are at elevated churn risk; commercial hiring may offset via geographic expansion.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo